Forward-loving: An Australian man has become the first person in the world to leave a hospital with total artificial heart transplants, an important milestone in the treatment of heart failure. He lived with the device for more than 100 days before receiving Donor Heart Transplant in early March – the longest recorded existence with this technique.
On November 22, 2024, a person received a man in his 40s in his 40s during his 40s during a six -hour process at St. Vincent Hospital in Sydney, a person received a Bivakor Total Artificial Heart (TAH). Operation, under the leadership of cardiothoresic and transplant surgeon Paul Janzz, as the University of Monash, which is for the heart front.
Australian bio-engineer Dr. Invented by Daniel Tims, the biver uses magnetic lensing techniques to repeat the natural blood flow of a healthy heart. Similar to the technique used in high-speed trains, it has a single moving part-eliminating the requirement of a levitated rotor-valve or mechanical bearings conducted in place by Maggate, which are prone to wear and tear.
https://www.youtube.com/watch?v=www3mmfmdobs
Bivacor Tah is designed from titanium, which has been chosen for its high bio -revision, corrosion resistance and strength. Designed to replace both ventricles of a failed heart, it serves as a life -saving bridge for patients waiting for a donor transplantation. The device pumps blood to both the body and lungs using a double-sided centrifugal impeller, which induces blood from individual pump chambers to pulmonary and systemic circulation.
Globally, more than 23 million people suffer from heart failure, yet only 6,000 get only one donor heart. To support the development and commercialization of the Bivacor device, the Australian government has invested $ 50 million in the program. Still in clinical trials and regulatory approval are waiting, the ability of the device to maintain patients for extended periods suggests that it can become a long -term solution for those facing heart failure.
Professor Chris Heword, Dr. Paul Janz and Dr. Daniel Tims
Bivacor Tah has already been tested in FDA’s initial feasibility study in the United States, where five patients have successfully received transplantation. These patients were supported by the device waiting for a donor transplant, with the longest support period lasting one month. The FDA has approved the expansion of the study to include more patients.
